Metin Kurtoglu - 03 Jan 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Reporting relationship: Chief Technology Officer
Issuer ticker: RNAC
Reported as of: 03 Jan 2025
Net transaction value: -$81,790
SEC form: 4
Accepted by SEC: 07 Jan 2025, 20:05:42 UTC
Prior SEC filing: 06 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Bartholomae, Attorney-in-Fact for Metin Kurtoglu

Key filing fact

Metin Kurtoglu filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 07 Jan 2025.

Key facts

This page summarizes Metin Kurtoglu's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 07 Jan 2025, 20:05.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Shares, units, or other non-derivative securities reported in this filing.

RNAC transaction

Sale

RNAC transaction

Sale

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.